A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.